

August 6, 2020

To Whom It May Concern,

Company Name: Taisho Pharmaceutical Holdings Co., Ltd.
Head Office: 3-24-1, Takada, Toshima-ku, Tokyo
Representative: Akira Uehara, Chief Executive Officer
(First Section of TSE: Code 4581)
Contact: Shinichi Tanaka, General Manager
Corporate Communications
(Tel: +81-3-3985-2020)

**Notice Concerning Determination of Details of Stock Options
(Stock Acquisition Rights)**

Taisho Pharmaceutical Holdings Co., Ltd. (“the Company”) announced that it has finalized the following matters regarding the issuance of stock options (subscription rights) announced on June 26, 2020, which had not been determined at the time. The Company resolved at its board of directors meeting held on June 26, 2020 to issue stock acquisition rights as stock options (Name: Taisho Pharmaceutical Holdings Co., Ltd. 9th Series of Stock Acquisition Rights) to the members of the board and other officers of the Company, along with the members of the board and other officers of Taisho Pharmaceutical Co., Ltd., a subsidiary of the Company.

(1)	Total number of stock acquisition rights	The total number of stock acquisition rights shall be 134. (The number of shares for each stock acquisition right shall be 100.)
(2)	Stock acquisition right allotment recipients and number of recipients	Members of the board of the Company (excluding outside directors) 6 individuals Corporate officer of the Company 1 individual Members of the board of Taisho Pharmaceutical Co., Ltd. (excluding outside directors) 7 individuals Other officers of Taisho Pharmaceutical Co., Ltd. 20 individuals
(3)	Amount to be paid per stock acquisition right	Amount to be paid per stock acquisition right: 605,300 yen (Amount per share: 6,053yen) (The Company shall offset the amount to be paid for the stock acquisition rights with compensation claimable from the Company by stock acquisition right allotment recipients.)